These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 29895521)

  • 21. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection.
    Trissel LA; Martinez JF; Gilbert DL
    J Am Pharm Assoc (Wash); 1999; 39(4):514-8. PubMed ID: 10467816
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
    Trissel LA; Martinez JF
    Am J Hosp Pharm; 1993 Nov; 50(11):2359-63. PubMed ID: 8266963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simulated Y-Site Compatibility of Vancomycin and Piperacillin-Tazobactam.
    Wade J; Cooper M; Ragan R
    Hosp Pharm; 2015 May; 50(5):376-9. PubMed ID: 26405323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
    Trissel LA; Martinez JF; Simmons M
    J Am Pharm Assoc (Wash); 1999; 39(2):141-5. PubMed ID: 10079649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Y-site physical compatibility of hydrocortisone continuous infusions with admixtures used in critically ill patients.
    Foushee JA; Meredith P; Fox LM; Wilder AG
    Am J Health Syst Pharm; 2020 Jul; 77(14):1144-1148. PubMed ID: 32537625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
    Trissel LA; Martinez JF
    Am J Hosp Pharm; 1994 Mar; 51(5):672-8. PubMed ID: 8203388
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Compatibility of amifostine with selected drugs during simulated Y-site administration.
    Trissel LA; Martinez JF
    Am J Health Syst Pharm; 1995 Oct; 52(20):2208-12. PubMed ID: 8564592
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Compatibility of micafungin injection with other drugs during simulated y-site co-administration.
    Trusley C; Kupiec TC; Trissel LA
    Int J Pharm Compd; 2006; 10(3):230-3. PubMed ID: 23974236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection.
    Trissel LA; Bready BB
    Am J Hosp Pharm; 1992 Jul; 49(7):1716-9. PubMed ID: 1352424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin.
    Zhanel GG; Lawson CD; Zelenitsky S; Findlay B; Schweizer F; Adam H; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Expert Rev Anti Infect Ther; 2012 Apr; 10(4):459-73. PubMed ID: 22512755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physical compatibility of cisatracurium with selected drugs during simulated Y-site administration.
    Foushee JA; Fox LM; Gormley LR; Lineberger MS
    Am J Health Syst Pharm; 2015 Mar; 72(6):483-6. PubMed ID: 25736944
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration.
    Kumar A; Mann HJ
    Am J Health Syst Pharm; 2010 Oct; 67(19):1640-4. PubMed ID: 20852166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stability and compatibility of fluorouracil and mannitol during simulated Y-site administration.
    Woloschuk DM; Wermeling JR; Pruemer JM
    Am J Hosp Pharm; 1991 Oct; 48(10):2158-60. PubMed ID: 1781472
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Compatibility of filgrastim with selected drugs during simulated Y-site administration.
    Trissel LA; Martinez JF
    Am J Hosp Pharm; 1994 Aug; 51(15):1907-13. PubMed ID: 7524319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures.
    Foushee JA; Meredith P; Fox LM; Grace E
    Int J Pharm Compd; 2016; 20(4):328-332. PubMed ID: 28333677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Visual compatibility of colistin injection with other antibiotics during simulated Y-site administration.
    Katip W
    Am J Health Syst Pharm; 2017 Jul; 74(14):1099-1102. PubMed ID: 28687555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
    Trissel LA; Martinez JF
    Am J Health Syst Pharm; 1996 May; 53(9):1041-5. PubMed ID: 8744467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Compatibility of Docetaxel with Selected Drugs during Simulated Y-Site Administration.
    Trissel LA; Gilbert DL; Wolkin AC
    Int J Pharm Compd; 1999; 3(3):241-4. PubMed ID: 23985624
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physical compatibility of Normosol-R with critical care medications used in patients with COVID-19 during simulated Y-site administration.
    Holyk AA; Lindner AH; Lindner SE; Shippert BW
    Am J Health Syst Pharm; 2022 Jan; 79(1):e27-e33. PubMed ID: 34390244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Compatibility screening of precedex during simulated y-site administration with other drugs.
    Trissel LA; Saenz CA; Ingram DS; Williams KY; Retzinger JP
    Int J Pharm Compd; 2002; 6(3):230-3. PubMed ID: 23979190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.